They setup the charter, dated 2018, specifically r
Post# of 148294
(Total Views: 584)
Posted On: 02/09/2020 4:37:08 AM
Re: crazyjogger925 #17548
They setup the charter, dated 2018, specifically referring to Nasdaq rules.
That was probably the ultimate goal and destination, which they have been chipping away at.
https://content.equisolve.net/_8fce186297d817...harter.pdf
I. PURPOSE
The purpose of the Compensation Committee (the “Committee”) of CytoDyn Inc. (the “Company”) is to: (i) discharge the responsibilities of the Board of Directors (the “Board”) relating to evaluation and compensation of the Company’s executives, (ii) oversee incentive, equity-based and other compensatory plans in which executive officers and key employees of the Company participate, (iii) review and determine director compensation and (iv) prepare any report on executive compensation required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and the listing standards of the NASDAQ Stock Market (“NASDAQ”).
II. COMPOSITION
The Committee shall be composed of two (2) or more directors, as determined by the Board, each of whom shall (i) be independent in accordance with the provisions of Rule 10C- 1(b)(1) under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and the rules of the NASDAQ, (ii) qualify as a “Non- Employee Director” for purposes of Rule 16b-3 under the Exchange Act, and (iii) qualify as an “outside director” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended.
Members shall satisfy the independence standards set forth in the applicable listing rules of the NASDAQ.
That was probably the ultimate goal and destination, which they have been chipping away at.
https://content.equisolve.net/_8fce186297d817...harter.pdf
I. PURPOSE
The purpose of the Compensation Committee (the “Committee”) of CytoDyn Inc. (the “Company”) is to: (i) discharge the responsibilities of the Board of Directors (the “Board”) relating to evaluation and compensation of the Company’s executives, (ii) oversee incentive, equity-based and other compensatory plans in which executive officers and key employees of the Company participate, (iii) review and determine director compensation and (iv) prepare any report on executive compensation required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and the listing standards of the NASDAQ Stock Market (“NASDAQ”).
II. COMPOSITION
The Committee shall be composed of two (2) or more directors, as determined by the Board, each of whom shall (i) be independent in accordance with the provisions of Rule 10C- 1(b)(1) under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and the rules of the NASDAQ, (ii) qualify as a “Non- Employee Director” for purposes of Rule 16b-3 under the Exchange Act, and (iii) qualify as an “outside director” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended.
Members shall satisfy the independence standards set forth in the applicable listing rules of the NASDAQ.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼